The pharmaceutical industry is currently focused on developing biologic drugs that target the FcRn receptor pathway to treat autoimmune diseases, with companies such as Argenx, Janssen, UCB and Immunovant competing to tackle myasthenia gravis. The 3rd Fc Receptor Pathway Targeted Therapies Summit will bring together experts in immunology, antibody
18-20 April 2023